Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Q24202950)

Elizabeth Tanjong Ghogomu

1

0 references

3

0 references

Claire Bombardier

7

0 references

Tamara Rader

6

object named as

Tamara Rader

0 references

George Wells

8

object named as

George A Wells

0 references

Zulma Ortiz

4

object named as

Zulma Ortiz

0 references

author name string

Michael V Swinden

2

0 references

Wanruchada Katchamart

Cochrane Database of Systematic Reviews

5

0 references

publication date

31 May 2013

0 references

published in

0 references

cites work

The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Folate supplementation and methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis. A metaanalysis of published clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Biological effects of folic acid antagonists with antineoplastic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Adalimumab for treating rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Low-dose methotrexate in rheumatic diseases--efficacy, side effects, and risk factors for side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Biologics for rheumatoid arthritis: an overview of Cochrane reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Does folate supplementation make sense in patients with rheumatoid arthritis treated with methotrexate?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Methotrexate in rheumatoid arthritis. Indications, contraindications, efficacy, and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Methotrexate in rheumatoid arthritis. Feedback on American College of Physicians guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000951.PUB2

Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial

21 January 2018

1 reference

12 December 2020

Folic acid supplementation during methotrexate therapy: it makes sense.

1 reference

12 December 2020

Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis. A double-blind, placebo-controlled trial

1 reference

12 December 2020

Concurrent use of folinic acid and methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis

1 reference

12 December 2020

Assessing the cost effectiveness of NSAID: an international perspective.

1 reference

12 December 2020

Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates

1 reference

12 December 2020

Efficacy of low-dose methotrexate in rheumatoid arthritis

1 reference

12 December 2020

Biologics for rheumatoid arthritis: an overview of Cochrane reviews

1 reference

12 December 2020

Administration of folinic acid after low dose methotrexate in patients with rheumatoid arthritis

1 reference

12 December 2020

Folate supplementation in methotrexate-treated rheumatoid arthritis patients

1 reference

12 December 2020

Toxicity of antirheumatic drugs. Toxicity Workgroup Leaders

1 reference

12 December 2020

Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial

1 reference

12 December 2020

A practical approach to avoidance of methotrexate toxicity

1 reference

12 December 2020

The effects of leucovorin (folinic acid) on methotrexate therapy in rheumatoid arthritis patients

1 reference

12 December 2020

Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention.

1 reference

12 December 2020

Folate status of rheumatoid arthritis patients receiving long-term, low-dose methotrexate therapy

1 reference

12 December 2020

Methotrexate for rheumatoid arthritis

1 reference

12 December 2020

Homocysteine levels in patients with rheumatoid arthritis treated with low-dose methotrexate

1 reference

12 December 2020

Abatacept for rheumatoid arthritis

1 reference

12 December 2020

Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis.

1 reference

12 December 2020

The changing face of therapy for rheumatoid arthritis

1 reference

12 December 2020

BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists

1 reference

12 December 2020

Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects

1 reference

12 December 2020

A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis

1 reference

12 December 2020

Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients

1 reference

12 December 2020

Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?

1 reference

12 December 2020

Methotrexate: the emerging drug of choice for serious rheumatoid arthritis.

1 reference

12 December 2020

10.1002/14651858.CD000951.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_c52zgj3a4ffwnels6nlqnx4p2u

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/c52zgj3a4ffwnels6nlqnx4p2u

24 November 2022